ConductScience.org, home

Paper22089340

Model-based meta-analysis for comparative efficacy and safety: application in drug development and beyond.

Mandema JW and 4 others. Clin Pharmacol Ther, 2011. Cited by 95 papers, by iCite.

Cite this record

ConductScience Library. Model-based meta-analysis for comparative efficacy and safety: application in drug development and beyond. Papers, record 22089340. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/22089340

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Model-based meta-analysis for comparative efficacy and safety: application in drug development and beyond.
PubMed
Journal
Clin Pharmacol Ther
PubMed
Year
2011
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't, Comment
PubMed
Citations, by iCite
95
iCite
Relative citation ratio, by iCite
2.7
iCite
Revised in PubMed
2018-12-01
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Mandema JWJ W
2Gibbs MM
3Boyd RAR A
4Wada DRD R
5Pfister MM

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antibodies, MonoclonalMajor topic
AnticoagulantsMajor topic
Antirheumatic AgentsMajor topic
Arthritis, RheumatoidMajor topic
Orthopedic ProceduresMajor topic
Venous ThromboembolismMajor topic
Humans

Source PubMed

Download CSV of topics

Comments and corrections2

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn PapersSource
Comment on22048227A dose-response meta-analysis for quantifying relative efficacy of biologics in rheumatoid arthritis.https://conductscience.org/library/papers/22048227PubMed
Comment on22048231Therapeutic index of anticoagulants for prevention of venous thromboembolism following orthopedic surgery: a dose-response meta-analysis.https://conductscience.org/library/papers/22048231PubMed

Download CSV of comments and corrections

Cited by56

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 95 citations.

PMIDTitleJournalYearIn PapersSource
42438069Current State-of-the-Art and Future Advancements of Model-Based Meta-Analysis.CPT Pharmacometrics Syst Pharmacol2026https://conductscience.org/library/papers/42438069PubMed
42085320MBMA Bridging Models as a Tool for Exploration of Clinical Endpoints in Unstudied Indications.CPT Pharmacometrics Syst Pharmacol2026https://conductscience.org/library/papers/42085320PubMed
41754991Systematic Review and Model-Based Meta-Analysis of Targeted Drugs for Systemic Sclerosis.Pharmaceutics2026https://conductscience.org/library/papers/41754991PubMed
41347637Model-Based Meta-Analysis With MonolixSuite: A Tutorial for Longitudinal Categorical and Continuous Data.CPT Pharmacometrics Syst Pharmacol2026https://conductscience.org/library/papers/41347637PubMed
41338640
Dose-effect relationship of intravenous tranexamic acid on perioperative haemoglobin drop in total hip arthroplasty (PRADO study): study protocol for a randomised, double-blind, placebo-controlled, dose-response study.
BMJ Open2025https://conductscience.org/library/papers/41338640PubMed
41023527Quantitative Evaluation of Nemolizumab Pharmacokinetics and Efficacy in Prurigo Nodularis: A Population Pharmacokinetics and Model-Based Meta-analysis Approach.Dermatol Ther (Heidelb)2025https://conductscience.org/library/papers/41023527PubMed
40326484Can Methotrexate Monotherapy Achieve Clinical Remission in Patients with Active Rheumatoid Arthritis? A Model-Based Meta-Analysis.J Clin Pharmacol2025https://conductscience.org/library/papers/40326484PubMed
40160292Pharmacodynamic Modeling of Cinacalcet in Secondary Hyperparathyroidism: Efficacy and Influencing Factors Analysis.J Endocr Soc2025https://conductscience.org/library/papers/40160292PubMed
39862179Quantitative evaluation of multiple treatment regimens for treatment-resistant depression.Int J Neuropsychopharmacol2025https://conductscience.org/library/papers/39862179PubMed
39379875Brain volume loss in relapsing multiple sclerosis: indirect treatment comparisons of available disease-modifying therapies.BMC Neurol2024https://conductscience.org/library/papers/39379875PubMed
39245866Partial Residual Plots as an Integrated Model Diagnostic Tool in Model-Based Meta-Analysis.Clin Pharmacol Ther2025https://conductscience.org/library/papers/39245866PubMed
38522000Model-based meta-analysis to quantify the effects of short interfering RNA therapeutics on hepatitis B surface antigen turnover in hepatitis B-infected mice.CPT Pharmacometrics Syst Pharmacol2024https://conductscience.org/library/papers/38522000PubMed
38308282Accelerating drug development for amyotrophic lateral sclerosis: construction and application of a disease course model using historical placebo group data.Orphanet J Rare Dis2024https://conductscience.org/library/papers/38308282PubMed
38183573Model-Based Meta-Analysis Supporting the Combination of Acetaminophen and Topical Diclofenac in Acute Pain: A Therapy for Mild-to-Moderate Osteoarthritis Pain?Pain Ther2024https://conductscience.org/library/papers/38183573PubMed
38183572Model-Based Assessment of the Liver Safety Profile of Acetaminophen to Support its Combination Use with Topical Diclofenac in Mild-to-Moderate Osteoarthritis Pain.Pain Ther2024https://conductscience.org/library/papers/38183572PubMed
37702936In Silico Clinical Trials: Is It Possible?Methods Mol Biol2024https://conductscience.org/library/papers/37702936PubMed
37507595LABA/LAMA versus LABA/ICS fixed-dose combinations in the prevention of COPD exacerbations: a modeling analysis of literature aggregate data.Eur J Clin Pharmacol2023https://conductscience.org/library/papers/37507595PubMed
37345104Difference in Efficacy and Safety of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Containing 4-1BB and CD28 Co-Stimulatory Domains for B-Cell Acute Lymphoblastic Leukemia.Cancers (Basel)2023https://conductscience.org/library/papers/37345104PubMed
37304299Comparation of time-course, dose-effect, influencing factors and adverse events of biologics in the treatment of adults with moderate to severe plaque psoriasis.Front Immunol2023https://conductscience.org/library/papers/37304299PubMed
36947282Joint longitudinal model-based meta-analysis of FEV1 and exacerbation rate in randomized COPD trials.J Pharmacokinet Pharmacodyn2023https://conductscience.org/library/papers/36947282PubMed

See all 56 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/22089340

GET https://conductscience.org/api/papers/v1/22089340/cited_by?page=2